MedTrace Logo

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2017-09-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether there are differences in the level of antibody to capsular polysaccharides of S. pneumoniae or the physiological activity of such antibody after vaccinating patients who have recovered from pneumococcal pneumonia with pneumococcal polysaccharide vaccine (Pneumovax) or conjugate pneumococcal vaccine (Prevnar).

Conditions

  • Pneumonia
  • Pneumococcal Infections
  • Infections, Streptococcus Pneumoniae

Interventions

BIOLOGICAL

Prevnar

0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)

BIOLOGICAL

Pneumovax

0.5 ml IM one time

Sponsors & Collaborators

  • Michael E. DeBakey VA Medical Center

    collaborator FED

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Daniel M Musher · Michael E. DeBakey VA Medical Center, Houston, TX

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-01
Primary Completion
2006-09-01
Completion
2012-06-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304382 on ClinicalTrials.gov